Since the approval of the cytotoxic T-lymphocyte associated protein-4 (CTLA-4) inhibitor ipilimumab for the treatment of patients with metastatic melanoma in 2011 [1,2], immune checkpoint inhibitors (ICIs) have revolutionized the management of cancer patients. The gene discussed is CTLA4; the disease is metastatic melanoma.